Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Few parts of the market have more volatility than the small caps in this sector.
A low-risk countertrend options trade may be worth a look in this name.
Here are updates on small biotech/biopharma names I have profiled before.
The way I do that is by using buy-write option strategies.
A close near the lows of the day will be a significant shift in the market action.
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.